FindMyKOL
Clinical trialNCT05722327Active, not recruitingPhase 1Interventional

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

NCT05722327 is a phase 1 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is active and no longer recruiting. It studies Cetuximab, Irinotecan and Adagrasib in Colon Cancer and Colorectal Cancer. The registry lists an enrollment of 24 participants at 1 site in 1 country. The registry lists a start date of 6 Dec 2023 and a primary completion date of 30 Sept 2027. One of its registered investigators has a FindMyKOL profile.

SponsorM.D. Anderson Cancer CenterEnrollment24Colon CancerColorectal Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05722327
FieldValue
Registry IDNCT05722327
StatusActive not recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment24
Registered sites1
Countries1
ConditionsColon Cancer and Colorectal Cancer
DrugsCetuximab, Irinotecan and Adagrasib
Start6 Dec 2023
Primary completion30 Sept 2027
Study completion30 Sept 2027
Last update posted14 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site
  • M D Anderson Cancer Center

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05722327

Each answer restates registry values shown on this page.

What is NCT05722327?

NCT05722327 is a phase 1 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Cetuximab, Irinotecan and Adagrasib in Colon Cancer and Colorectal Cancer.

Is NCT05722327 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT05722327?

The registry names David S. Hong, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT05722327 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05722327 study?

The registered drug and biological interventions are Cetuximab, Irinotecan and Adagrasib.

When is NCT05722327 expected to complete?

The registry lists a primary completion date of 30 Sept 2027 and a study completion date of 30 Sept 2027. The sponsor last updated the record on 14 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.